Aspire Biopharma Holdings, Inc.

NASDAQ: ASBP · Healthcare · Biotechnology

PublicHQ Estero, FL · LeeCIK 0001847345Reports USD

#1139 of 1,418 Healthcare companies by revenue

EA Score

17D

FH 21DQ 12GM —SS 13

v0.1 · 55/100 weight · provisional

↑ Piotroski F, Altman-Z · ↓ disclosure history, operating margin

Methodology →

Revenue TTM

$97.7k

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$24.5M

Employees

as of 2026-08-26

Market cap

$954.1k

as of 2026-08-26

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$6.2k$6.2k2025

Net income-$24.5M-$24.5M2025

Operating income-$19.4M-$19.4M2025

Total assets$1.3M$1.3M2025

Liabilities$7.7M$7.7M2025

Equity-$6.4M-$6.4M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Aspire Biopharma Holdings, Inc.’s revenue?

Aspire Biopharma Holdings, Inc. booked $6.2k in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -394725.1% net margin.

Peers · Healthcare

Genelux Corporation32D Better Therapeutics, Inc.——Kaya Holdings, Inc.——Creative Medical Technology Holdings, Inc.46D Alaunos Therapeutics, Inc.33D One World Products, Inc.——

Neighbors

Lee →

Herc Holdings Inc.$862.0M57C Hertz Global Holdings, Inc.$244.0M48D NeoGenomics, Inc.$727.3M72B Alico, Inc.$44.1M50D American Oncology Network, Inc.$1.8B——Innovative Food Holdings, Inc.$60.7M57C

Key facts

CEOKraig T. Higginson

SectorHealthcare

IndustryBiotechnology

HeadquartersEstero, FL

ExchangeNASDAQ: ASBP

Employees2

IPO date2025-02-20

Latest filings

8-K2026-08-19 10-Q2026-08-13 8-K2026-08-10 8-K2026-07-20 8-K2026-06-22 8-K2026-06-12 8-K2026-06-12 10-Q2026-05-15

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.